PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Y-Biologics is pursuing early licensing deals with global pharma using its Multi-AbKine antibody-cytokine fusion platform, but its revenue base remains small and losses have widened in recent quarters.
FY2025 consolidated revenue was KRW 2.91bn with an operating loss of KRW 9.27bn and an owners' net loss of KRW 42.02bn, a sharp widening from the prior year
Q4 2025 net loss ballooned to KRW 35.1bn, accounting for most of the annual loss, and quarterly losses continued widening to KRW 4.3bn and KRW 7.8bn in Q1 and Q2 2026
Preclinical data on AR170 and AR166 (Multi-AbKine-based) presented at AACR 2026 drew interest from multinational pharma, and the company held 24 partnering meetings at BIO USA 2026
The company appointed business-development veteran Beomchan Park as co-CEO in July 2026, signaling a strengthened licensing-focused strategy
The company has a track record of eight cumulative licensing deals (3D Medicines, Pyxis Oncology, Pierre Fabre, HK inno.N, etc.), but whether further large deals materialize remains the key question
Y-Biologics is an antibody drug development company with the Ymax-ABL antibody discovery platform, the ALiCE T-cell bispecific platform, and the Multi-AbKine antibody-cytokine fusion platform.
Its lead pipeline is aclrelimab (YBL-006), a PD-1-targeting immune checkpoint inhibitor in global Phase 1/2a trials for solid tumors, while YBL-013, a PD-L1xCD3 bispecific built on the ALiCE platform, was licensed to China's 3D Medicines and is now undergoing CMC and GLP toxicology studies for regulatory filing.
Recent research focus has shifted toward next-generation candidates AR170 and AR166 under the Multi-AbKine platform, which fuse IL-2 variants (IL-2v) onto a PD-1 axis; preclinical data on both were unveiled at the AACR 2026 meeting in April.
The business model rests on three pillars: licensing of proprietary pipelines, co-development with partners, and contract research services. As of Q1 2026, a substantial portion of revenue came from contract research services, underpinning a relatively stable cash-flow component of the business.
Co-development pipelines with partners include YBL-001 (an ADC with LegoChem Biosciences), YBL-015 (an ADC with Intocell), and YBL-034 (an autoimmune candidate with HK inno.N).
The company has a track record of eight completed licensing deals to date with counterparties including 3D Medicines, Pyxis Oncology, Pierre Fabre, and HK inno.N.
Industry observers note that few domestic companies possess a full generational suite of technology from discovery through bispecific and multi-specific antibodies.
In July 2026, business-development specialist Beomchan Park was appointed co-CEO, a move expected to further strengthen the company's licensing-centered strategy.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩1.2B | -₩1.5B | −128.4% |
| 2025Q3 | ₩900M | -₩2.5B | −283.5% |
| 2025Q4 | ₩400M | -₩3B | −665.5% |
| 2026Q1 | ₩300M | -₩3.9B | −1376.4% |
| 2026Q2 | ₩1.5B | -₩3.8B | −244.9% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩4.2B | -₩18.8B | -₩18.8B | −453.7% | −153.0% | 138.5% |
| 2023 | ₩3.5B | -₩10.1B | -₩20.9B | −291.5% | −89.2% | 29.4% |
| 2024 | ₩5.8B | -₩8.4B | -₩6.4B | −146.6% | −35.1% | 18.4% |
| 2025 | ₩2.9B | -₩9.3B | -₩42B | −318.2% | −158.0% | 109.8% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-05
Consolidated revenue in 2025 was KRW 2.91bn, sharply down from KRW 5.76bn in 2024, while the operating loss widened to KRW 9.27bn from KRW 8.45bn a year earlier.
The operating margin deteriorated to -318.2% from -146.6% in 2024, and comparing this with -291.5% in 2023 and -453.7% in 2022 shows substantial year-to-year swings.
The owners' net loss reached KRW 42.02bn, more than six times the KRW 6.44bn loss in 2024, an outcome driven overwhelmingly by a single-quarter net loss of KRW 35.11bn in Q4 2025.
Quarterly losses had been KRW 2.34bn in Q2 2025 and KRW 2.69bn in Q3 2025 before expanding sharply in Q4; the large gap between the operating loss (KRW 2.99bn) and net loss (KRW 35.11bn) that quarter suggests a sizable non-operating item was recorded, though the specific detail requires further confirmation.
Losses continued widening into 2026, with net losses of KRW 4.32bn in Q1 and KRW 7.83bn in Q2. Over the most recent four quarters (Q3 2025 through Q2 2026), cumulative revenue totaled KRW 3.17bn while the cumulative net loss reached KRW 49.95bn, exceeding the full-year 2025 loss.
Operating cash flow was also negative at KRW -5.84bn in 2025, compared with KRW -4.14bn in 2024 and KRW -7.61bn in 2023, indicating the company has yet to establish stable operating cash generation.
Total equity rose from KRW 18.36bn in 2024 to KRW 26.60bn in 2025, but total liabilities also jumped from KRW 3.37bn to KRW 29.20bn, pushing the debt ratio up from 18.4% to 109.8%, a notable shift in the balance-sheet structure.
Across the global pharma and biotech industry, there is a clear push to secure preclinical-stage multi-specific antibody technologies early in order to strengthen next-generation immuno-oncology portfolios.
In Q2 2026 alone, multi-billion-dollar deals were struck between BMS and Akeso (Hengrui Pharmaceuticals), Pfizer and Innovent, and BeOne Medicines (formerly BeiGene) and Huahui Health, underscoring active licensing at the early molecule stage.
Notably, in April BeOne Medicines in-licensed a PD-1xCTLA-4xVEGF-A trispecific candidate for a deal valued at $2 billion, marking the first global trispecific deal, after which market attention appeared to shift from bispecifics toward trispecifics.
That said, given that the underlying data originated from a Chinese biotech, global market assessments remain reported as mixed.
Y-Biologics is seen as having built competitiveness in the PD-1xVEGF-IL-2 trispecific-style approach through its Multi-AbKine platform, a positioning that aligns with the direction in which market attention is moving.
On the other hand, competitive intensity remains elevated given the number of domestic platform-based antibody developers and the fast pace of similar-modality development among Chinese and U.S. biotechs.
Ultimately, the industry's key determinant is the quality of preclinical data and how quickly follow-on data such as CMC and GLP toxicology results can be secured to meet big pharma due-diligence standards.
The company has stated plans to raise the likelihood of early licensing for its Multi-AbKine pipeline candidates AR170 and AR166 based on CMC and GLP toxicology results expected in the second half of this year.
Among the 24 companies met at BIO USA 2026, some reportedly shared strategies of considering in-licensing preclinical-stage candidates if efficacy, toxicity, and development feasibility meet their internal criteria.
The company plans to continue sharing forthcoming data with these big pharma counterparts to advance follow-on discussions.
Beomchan Park, who led the partnering meetings, noted that final agreements with big pharma typically follow months of ongoing data updates, and said the company plans to continue discussions at BIO-Europe and the JPMorgan Healthcare Conference in early next year.
The company has also established a translational research team in Seoul's Mundeong-dong and begun mechanism-of-action research using patient-derived tissue samples in collaboration with major domestic hospitals and KAIST, with plans to enhance pipeline value by supplementing mechanism data from cancer patient tissue by year-end.
For YBL-013, partner 3D Medicines is conducting CMC and GLP toxicology studies for regulatory filing within China, while separate discussions on global licensing outside China are also reportedly underway.
Whether the appointment of a business-development specialist as co-CEO translates into an actual signed licensing deal will likely be the key determinant of earnings improvement going forward.
With persistent net losses keeping earnings per share negative, the company sits in a range where conventional price-to-earnings calculation is not meaningful.
At the same time, the share price trades at a level well above the company's book value per share, placing it in a segment with a substantial premium to net assets. The absence of a recent dividend track record means dividend yield is not a feature of the investment case.
Looking at the multi-year earnings trend, the net loss narrowed relatively in 2024 before widening again through 2025 and 2026, so a clear profitability recovery has not yet materialized.
Ultimately, the current valuation can be interpreted as reflecting market expectations around pipeline licensing potential and platform technology rather than realized earnings.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-05
The company has completed eight licensing deals to date with counterparties including 3D Medicines, Pyxis Oncology, Pierre Fabre, and HK inno.N. This can be interpreted as external validation of its platform technology and may support the potential for further deals going forward. However, past deals do not guarantee future new agreements.
As global market attention shifts from bispecifics to trispecifics, the company's Multi-AbKine platform is regarded as competitive in the PD-1xVEGF-IL-2 category. Big pharma interest in this modality has been confirmed through cases such as BeOne Medicines' $2 billion trispecific in-licensing deal.
However, it should also be considered that assessments remain mixed given that the benchmark data originated from a Chinese biotech.
The July 2026 appointment of business-development veteran Beomchan Park as co-CEO provides organizational support for a licensing-centered strategy. CEO Youngwoo Park was confirmed to have recently purchased 18,000 shares of treasury stock on the open market.
Contract research service revenue has been maintained at a certain level, meaning cash flow has not been completely cut off.
After the net loss widened to KRW 35.1bn in Q4 2025, net losses continued at KRW 4.3bn and KRW 7.8bn in Q1 and Q2 2026, respectively. The cumulative net loss over the most recent four quarters reached KRW 49.95bn, exceeding the full-year 2025 loss. With a small revenue base, losses have continued to widen structurally.
Total liabilities in 2025 rose sharply to KRW 29.20bn from KRW 3.37bn a year earlier, pushing the debt ratio from 18.4% up to 109.8%. While total equity also increased, liabilities grew at a faster pace, weakening balance-sheet health indicators. With losses persisting, the need for additional funding could increase.
Revenue relies heavily on contract research service fees and licensing payments, resulting in large quarterly volatility. Revenue fell to KRW 2.91bn in 2025 from KRW 5.76bn a year earlier, roughly halving, and swung sharply within 2026 from KRW 0.28bn in Q1 to KRW 1.55bn in Q2.
The timing and scale of any new major licensing deal depend on the counterpart big pharma's decision-making, a variable largely outside the company's control.
Global big pharma companies typically finalize agreements only after months of ongoing data updates. If the company's targeted CMC and GLP toxicology data are delayed, the timeline for early licensing could also slip. Both the occurrence and timing of any deal remain uncertain.
Persistent net losses and negative operating cash flow could create a need for additional funding going forward. The debt ratio's sharp rise to 109.8% in 2025 is also a point warranting attention to financial flexibility. If further capital is raised, dilution for existing shareholders cannot be ruled out.
As global market attention rapidly shifts from bispecific to trispecific antibodies, the relative appeal of existing bispecific assets could diminish. The pace of similar-modality development among Chinese and U.S. biotechs is fast, intensifying competition.
It should also be noted that many benchmark large deals are based on data originating from Chinese biotechs, meaning the evaluation standards themselves remain fluid.
Check whether the company attends BIO-Europe and whether follow-on partnering discussions with big pharma advance.
Check whether CMC and GLP toxicology data for the Multi-AbKine pipeline (AR170, AR166) are secured, and how the results affect early licensing discussions.
Check whether the plan to secure mechanism-of-action data from patient-derived tissue samples is completed.
Check the Q3 2026 earnings disclosure for whether the trend of widening quarterly losses continues and how the equity/liability structure changes.
Check for follow-on partnering progress and any new licensing deal announcements arising from participation in the JPMorgan Healthcare Conference.
Y-Biologics is pursuing early licensing deals with global big pharma on the back of its Multi-AbKine platform and an eight-deal licensing track record, but losses have widened rather than narrowed through 2025 and the first half of 2026.
Net losses of KRW 35.1bn in Q4 2025 and KRW 4.3bn and KRW 7.8bn in Q1 and Q2 2026 pushed the cumulative loss over the most recent four quarters above the full prior-year figure. Over the same period, the debt ratio jumped from 18.4% to 109.8%, reflecting a shift in the balance-sheet structure.
The appointment of a business-development veteran as co-CEO and insider open-market share purchases signal organizational commitment to licensing, but converting this into an actual signed deal requires CMC and GLP toxicology data along with months of big pharma due diligence.
While industry observers note the company's positioning aligns with the market's shift in attention toward trispecific antibodies, differing views persist over the source of benchmark data and the intensity of competition.
Investors should continue tracking upcoming events such as BIO-Europe, Q3 earnings, year-end mechanism data, and the JPMorgan Healthcare Conference to gauge real progress in both earnings and business-development outcomes.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.